Patents by Inventor Galen D. Knight

Galen D. Knight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Beta-alethine use in cell culture and therapy
    Publication number: 20040110680
    Abstract: &bgr;-alethine is employed in the differentiation, phenotypic expression, and vitalization of cells, for both in vivo and in vitro applications. Particular applications include the use of &bgr;-alethine in the treatment of immune disorders and diseases, and in the promotion of cell cultures.
    Type: Application
    Filed: August 8, 2003
    Publication date: June 10, 2004
    Applicant: Regents of the University of New Mexico
    Inventors: Galen D. Knight, Paul L. Mann, Terence J. Scallen
  • Use of vitaletheine modulators in the prophylaxis and treatment of disease
    Publication number: 20030166715
    Abstract: Sulfur-containing derivatives of carboxy-amino-amides are provided for use, inter alia, in treating diseases or disorders.
    Type: Application
    Filed: December 4, 2001
    Publication date: September 4, 2003
    Inventors: Galen D. Knight, Terence J. Scallen
  • In vitro cell culture in media containing beta-alanyl-taurine or carbobenzoxy beta-alanyl-taurine
    Patent number: 6323025
    Abstract: Compounds termed “vitaletheine modulators” which include beta-alanyl-taurine and carbobenzoxy beta-alanyl-taurine are synthesized and added to culture media for in vitro culture of cells such as mammalian or plant cells. The compounds support cell vitality, and provide increased cellular life span, increased cellular bioproductivity, improved cellular function, and adaption of resistant cells to culturing. The compounds further delay senescence, optimize growth and maturation, and increase population doublings.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 27, 2001
    Assignee: University of New Mexico
    Inventors: Galen D. Knight, Terence J. Scallen
  • &bgr;-alethine use in cell culture and therapy
    Patent number: 6245561
    Abstract: &bgr;-alethine is employed in the differentiation, phenotypic expression, and vitalization of cells, for both in vivo and in vitro applications. Particular applications include the use of &bgr;-alethine in the treatment of immune disorders and diseases, and in the promotion of cell cultures.
    Type: Grant
    Filed: November 22, 1994
    Date of Patent: June 12, 2001
    Assignee: University of New Mexico
    Inventors: Galen D. Knight, Paul L. Mann, Terence J. Scallen
  • In vitro cell culture in media containing beta-alanyl-taurine or carbobenzoxy beta-alanyl-taurine
    Patent number: 6096536
    Abstract: Compounds termed "vitaletheine modulators" which include beta-alanyl-taurine and carbobenzoxy beta-alanyl-taurine are synthesized and added to culture media for in vitro culture of cells such as mammalian or plant cells. The compounds support cell vitality, and provide increased cellular life span, increased cellular bioproductivity, improved cellular function, and adaption of resistant cells to culturing. Carbobenzoxy beta-alanyl-taurine is produced by coupling .beta.-alanine, which has it's terminal amine protected with a carbobenzoxy (CBZ) group, to N-hydroxysuccinimide to produce an active ester of .beta.-alanine, coupling two of the active esters to cystamine to produce a CBZ-protected .beta.-alethine having an internal disulfide bond, isolating and purifying the CBZ-protected .beta.-alethine, and reacting the CBZ-protected .beta.-alethine with iodine to oxidize the disulfide bond to obtain carbobenzoxy beta-alanyl-taurine.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 1, 2000
    Assignee: University of New Mexico
    Inventors: Galen D. Knight, Terence J. Scallen
  • .beta.-alethine as anti-tumor agent
    Patent number: 6046241
    Abstract: .beta.-alethine is identified as an anti-tumor agent.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 4, 2000
    Assignee: University of New Mexico
    Inventors: Galen D. Knight, Paul L. Mann, Terrance J. Scallen
  • .beta.-alethine as anti-tumor agent
    Patent number: 5643966
    Abstract: .beta.-alethine is identified as an anti-tumor agent.
    Type: Grant
    Filed: October 3, 1994
    Date of Patent: July 1, 1997
    Assignee: University Of New Mexico
    Inventors: Galen D. Knight, Paul L. Mann, Terrance J. Scallen
  • Therapeutic use of vitaletheine modulators in neoplasia
    Patent number: 5578313
    Abstract: A method for treating neoplasia using sulfur-containing derivatives of carboxy-amino-amides, comprising vitaletheine and vitalethine and related compounds, is provided.
    Type: Grant
    Filed: October 4, 1994
    Date of Patent: November 26, 1996
    Assignee: The University of New Mexico
    Inventors: Galen D. Knight, Terence J. Scallen
  • Therapeutic use of vitaletheine modulators in neoplasia
    Patent number: 5370868
    Abstract: A method for treating neoplasia using sulfur-containing derivatives of carboxy-amino-amides, comprising vitaletheine and vitalethine and related compounds, is provided.
    Type: Grant
    Filed: August 13, 1992
    Date of Patent: December 6, 1994
    Assignee: University of New Mexico
    Inventors: Galen D. Knight, Terence J. Scallen